Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-Drug Resistance.)
Secondary Data Collection Study; safety and effectiveness of Tigecycline .under Japanese medical practice
Observational Model: Case-Only Time Perspective: Retrospective
Target Follow-Up Duration
The patients whom an investigator involving B1811187 prescribes the tigecycline (Tygacil).
Skin Disease, Infectious
Drug: Tigecycline (Tygacil)
Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Other Name: Tygacil, Tigecycline
Subjects who are treated with tigecycline
Intervention: Drug: Tigecycline (Tygacil)
* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Actual Enrollment (submitted: August 16, 2017)
Original Estimated Enrollment (submitted: February 8, 2013)
Actual Study Completion Date
June 16, 2017
Actual Primary Completion Date
June 16, 2017 (Final data collection date for primary outcome measure)
All patients who are prescribed tigecycline (Tygacil).
Subject who have not been prescribed tigecycline (Tygacil).
Sexes Eligible for Study:
Child, Adult, Older Adult
Accepts Healthy Volunteers
Contact information is only displayed when the study is recruiting subjects
Listed Location Countries
Removed Location Countries
Other Study ID Numbers
Has Data Monitoring Committee
U.S. FDA-regulated Product
IPD Sharing Statement
Plan to Share IPD:
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
Pfizer CT.gov Call Center
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below: